Tag: Cancer: Ovarian
Adjuvant Hormone Tx Ups Survival in Epithelial Ovarian CA
Significant improvement in overall, relapse-free survival for women receiving five-years of AHT
Eudaimonic Well-Being Tied to Ovarian Tumor Neuroeffector
Positive affect, psychological distress not associated with tumor norepinephrine
Nonselective Beta-Blocker Use Ups Survival in Ovarian Cancers
Longer median overall survival for patients receiving any beta-blocker versus nonusers
RAD51 Mutations Confer Moderate Risk of Ovarian Cancer
RAD51C and RAD51D deleterious mutations linked to increased risk of epithelial ovarian cancer
Multigene Test IDs More at Risk for Hereditary Breast/Ovarian CA
Testing for mutations other than BRCA1/2 in HBOC may change clinical management for women, families
~30 Percent With Epithelial Ovarian CA Survive Long Term
Predictors for long-term survival include younger age, early stage, low grade, non-serous histology
Intraperitoneal Chemotherapy Ups Ovarian Cancer Outcomes
However, only 41 percent of suitable candidates actually receive the therapy
Novel Pharmacological Activity for R-Ketorolac in Ovarian Cancer
R-enantiomer enriched in peritoneal fluids, inhibits peritoneal cell GTPase activity
Worse Survival With Chemo Dose Reduction in Ovarian Cancer
Lower average relative dose intensity linked to worse overall and ovarian cancer-specific survival
Benefits for Surgery Before Chemo in Advanced Ovarian CA
Appears to raise quality of life without shortening survival
